how were glp 1 drugs discovered GLP-1-based therapies for diabetes, obesity and beyond GLP-1 receptor assay: drug discovery

CT-388 is investigational and not yet FDA-approved Phase 2 data are from 469 patients over 48 weeks

The promise of retatrutide is that a single molecule may coordinate several pathways at once

This leads to dose-dependent weight loss (typically 8-15% in monotherapy trials), with additive effects when combined with GLP-1 agonists like semaglutide due to complementary mechanisms on energy balance and gastrointestinal function

Longitudinal studies in spontaneously hypertensive stroke-prone have demonstrated that gut dysbiosis precedes the onset of hypertension and is marked by shifts in bacterial community structure and altered tryptophan-kynurenine metabolism, implicating microbial pathways in the early development of hypertension and related neurovascular complications (Shi et al., 2022)

Their study on graying has just been published in Nature, and the results offer new insights into how stress can impact the body

This decline from 200 ng/mL to 80 ng/mL correlates directly with decreased regenerative capacity and visible signs of aging